NCT Number: NCT03523676
Use of Red Cell Distribution Width for Prediction of New-onset Atrial Fibrillation in Critically Ill Sepsis Patients
Red cell distribution width variations are increased in a variety of medical conditions such as congestive heart failure, acute myocardial infarction, pulmonary embolism, pneumonia, critical illness, and cardiac arrest , and is a predictor of mortality in the general population..
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–65 year
Sex eligibility
All sexes
Study type
Observational
About this study
This study was done retrospectively on sepsis patients admitted to intensive care units. data will be retrieved from patient medical records. The primay end point will be occurrence of new-onset AF during ICU stay. The secondary outcomes will be 28-day mortality.
The presence of anisocytosis or RDW variations has been classicaly used as a test for iron deficiency anemia. Increasing evidence points to its potential as a predictor for various conditions such as heart failure , malignancy, ischemic heart disease and sepsis.
Study investigators will examine the relationship between RDW levels and incidence of atrial fibrillation in critically ill sepsis patients as well as 28-day mortality.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- For all patients According to Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) , adult patients with suspected infection are identified, having quickSOFA (qSOFA) score meeting ≥2 of the following criteria: respiratory rate of 22/min or greater, altered mentation, or systolic blood pressure of 100 mmHg or less
- Sepsis patients with newly developed Atrial fibrillation during ICU stay.
Exclusion criteria
All patients with concomitant valvular disease, cardiomyopathy, cardiac dysrhythmias, previous cardiac surgery, secondary hypertension, hyperthyroidism, severe head injury, stroke, coma, acute coronary artery disease or underlying cardiac dysfunction[cardiac index (CI) <2.2 l/min/m 2 ], severe liver disease (Child-Pugh grade C), chronic renal failure were excluded from the study. In addition, pregnant patients were excluded.
Treatment and study plan
Primary outcomes
-
New-Onset atrial fibrillation , confirmed by electrocardiographical assessment
Time frame: 7 days
Sponsors and collaborators
Lead sponsor
Ain Shams University
Other
Registry information
Official study title
Evaluation of Red Cell Distribution Width to Predict New-onset Atrial Fibrillation in Critically Ill Sepsis Patients
Important dates
- Study start
- 2017
- Primary completion
- 2018
- Study completion
- 2018
- First posted
- May 14, 2018
- Registry last updated
- May 14, 2018
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Effect of Left Posterior Pericardiotomy for the Prevention of POAF
NCT06159985
Arterial Occlusive Diseases, Arteriosclerosis
Seoul, South Korea
View Trial DetailsColchicine for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement
NCT04870424
Atrial Fibrillation New Onset, Colchicine
Bern, Switzerland
View Trial DetailsA Pharmaco-surgical Approach to Reduce Postoperative Atrial Fibrillation After Cardiac Surgery
NCT05780320
Atrial Fibrillation New Onset
Boston, Massachusetts, United States
View Trial DetailsSTOP AF First: Cryoballoon Catheter Ablation in an Antiarrhythmic Drug Naive Paroxysmal Atrial Fibrillation
NCT03118518
Arrhythmias, Cardiac, Atrial Fibrillation
Birmingham, Alabama, United States
View Trial Details